Related Experiment Video
Updated: May 31, 2026
Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
Published on: March 30, 2022
Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis
Hans D Theiss1, Markus Vallaster, Christoph Rischpler
1Medical Department I, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany.
Insights
Dual stem cell therapy improves heart function after myocardial infarction by enhancing stem cell homing via the SDF-1/CXCR4 axis. Blocking this pathway reverses therapeutic benefits, proving its essential role.
Area of Science:
- Cardiovascular Research
- Stem Cell Biology
- Regenerative Medicine
Background:
- Dual stem cell therapy, combining G-CSF and DPP-IV inhibition, enhances cardiac function and survival post-myocardial infarction.
- The precise mechanisms, including the SDF-1/CXCR4 axis, resident cardiac stem cell stimulation, and myocardial perfusion, remain incompletely understood.
Purpose of the Study:
- To elucidate the critical role of the SDF-1/CXCR4 axis in mediating the benefits of dual stem cell therapy.
- To determine if dual stem cell therapy's efficacy relies on SDF-1/CXCR4-mediated stem cell homing and resident stem cell activation.
Main Methods:
- Utilized a mouse model of myocardial infarction with surgically induced LAD ligation.
- Administered G-CSF and Diprotin A (dual therapy) and blocked SDF-1/CXCR4 interactions using the antagonist AMD3100.
- Assessed stem cell homing (FACS), cardiac remodeling (histology), heart function (catheterization), and survival (Kaplan-Meier curves).
Main Results:
- AMD3100 treatment significantly reduced circulating stem cell homing to the infarct zone.
- Blocking the SDF-1/CXCR4 axis reversed the beneficial effects on cardiac remodeling, heart function, and survival.
- Dual stem cell therapy enhanced neovascularization and myocardial blood flow, and stimulated resident cardiac stem cells, effects abolished by AMD3100.
Conclusions:
- Homing of stem cells via the SDF-1/CXCR4 axis is indispensable for the therapeutic success of dual stem cell therapy.
- These findings confirm the SDF-1/CXCR4 pathway as a key mediator of stem cell-based cardiac repair.
Background:
G-CSF based stem cell mobilization and stabilization of cardiac SDF-1 by DPP-IV-inhibition (dual stem cell therapy) improve heart function and survival after myocardial infarction. However, it is barely understood whether this new approach acts specifically through the SDF-1/CXCR4 axis, stimulation of resident cardiac stem cells and improved myocardial perfusion. Therefore, we aimed to clarify the role of the SDF1/CXCR4 axis with respect to the benefits of a dual stem cell based therapy.
Methodology/Principal Findings:
After surgically induced ligation of the LAD, SDF-1/CXCR4 interactions were specifically blocked by the CXCR4 receptor antagonist AMD3100 in G-CSF and Diprotin A treated C57BL/6 mice. G-CSF+DipA treated and non-treated animals served as controls. Because AMD3100 is known to mobilize bone marrow derived stem cells (BMCs) in high concentrations, the optimal dosage (1.25mg per kg body weight) sufficient to block CXCR4 without stimulating mobilization was established. AMD3100 treatment of G-CSF and Diprotin A stimulated mice significantly decreased myocardial homing of circulating stem cells (FACS analysis) and inverted the beneficial effects of (i) cardiac remodeling (histological analyses), (ii) heart function (Millar tip catheterization) and (iii) survival (Kaplan-Meier curves). G-CSF treatment in combination with DPP-IV inhibition enhanced neovascularization at the infarct border zone which was related to an improved myocardial blood flow as measured by SPECT. Moreover, dual stem cell treatment effectively stimulated the pool of resident cardiac stem cells (FACS) which was reversed by AMD3100 treatment.
Conclusions/Significance:
Our data give final proof that homing through the SDF-1/CXCR-4 axis is essential for the success of dual stem cell therapy.
